Jazz Pharmaceuticals plc — Director's Dealing 2017

Aug 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2017-08-10

Reporting Person: RIEDEL NORBERT G (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-10	Ordinary Shares	A	1365	$0.0	Acquired	6318	Direct
2017-08-11	Ordinary Shares	S	659	$142.36	Disposed	5659	Direct
2017-08-11	Ordinary Shares	S	3	$144.1307	Disposed	5656	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-10	Non-Qualified Stock Option (right to buy)	$143.66	A	3415	Acquired	2027-08-09	Ordinary Shares (3415)	Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on August 3, 2018.

F2: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.

F3: These options are granted pursuant to the Issuer's 2007 Non-Employee Directors Stock Award Plan. Subject to the Reporting Person's continuous service and certain additional conditions, these options will vest in 12 equal monthly installments beginning on September 1, 2017.